STOCK TITAN

Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, will engage in a virtual fireside chat at the 13th Annual Wedbush PacGrow Healthcare Conference. The event is scheduled for August 10, 2022, at 12:00 p.m. ET. Interested parties can access a live webcast via the Arcus Biosciences website, with a replay available post-event. Founded in 2015, Arcus is advancing six investigational medicines aimed at targeting cancer pathways.

Positive
  • None.
Negative
  • None.

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference. The fireside chat will take place on Wednesday, August 10th, 2022 at 12:00 p.m. ET.

A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Media Inquiries

Holli Kolkey

VP of Corporate Communications

(650) 922-1269

hkolkey@arcusbio.com

Investor Inquiries

Pia Banerjee

Head of Investor Relations & Strategy

(617) 459-2006

pbanerjee@arcusbio.com

Source: Arcus Biosciences

FAQ

What is the date and time of Arcus Biosciences' fireside chat at the Wedbush PacGrow Healthcare Conference?

The fireside chat will take place on August 10, 2022, at 12:00 p.m. ET.

Where can I watch the Arcus Biosciences fireside chat?

You can access the live webcast on the Arcus Biosciences website in the 'Investors & Media' section.

What is the focus of Arcus Biosciences as a biopharmaceutical company?

Arcus Biosciences focuses on developing differentiated molecules and combination medicines for cancer.

When was Arcus Biosciences founded?

Arcus Biosciences was founded in 2015.

How many investigational medicines has Arcus Biosciences developed?

Arcus Biosciences has expedited the development of six investigational medicines.

Arcus Biosciences, Inc.

NYSE:RCUS

RCUS Rankings

RCUS Latest News

RCUS Stock Data

1.41B
54.37M
40.6%
60.08%
8.27%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HAYWARD